ITHEMICAL: Feasibility of Constraint-induced Therapy Combined With Visual-spatial Cueing Strategy in Patients With Acute Stroke

Sponsor
Nantes University Hospital (Other)
Overall Status
Terminated
CT.gov ID
NCT03754166
Collaborator
(none)
8
1
2
12.8
0.6

Study Details

Study Description

Brief Summary

The aim of this study is to test the feasibility of a constraint intervention combined with visual-spatial cueing strategy in patients with acute stroke to improve their daily life activities.

Condition or Disease Intervention/Treatment Phase
  • Other: Constraint-induced movement therapy
N/A

Detailed Description

As part of treatment in acute stroke (from D0 to D14), the investigators were able to observe that despite motor recovery during physiotherapy sessions, it remained difficult for some patients to use their affected arm (AA) during activities of daily life (ADL). This mechanism of "learned non-use" would be due to a cognitive process decreasing the use of the AA and could partly explain that 75% of patients maintain an upper limb deficit at 3-6 month post-stroke.

In order to combat this phenomenon, a bottom up method (sensorimotor action on the deficit) of constraint-induced movement therapy (CIMT) has been developed and consists in immobilizing the unaffected arm to force the use of the AA.

This technique has proved its effectiveness in the chronic phase and has also recently been proven to improve motor performance in the acute phase. Transposing progress on ADL, however, remains difficult because CIMT does not contain adequate behavioral strategies.

To help the patient mobilize these strategies, coupling of CIMT with a top-down method (conscious action on motor skills) has been successfully tested as an intervention of an occupational therapist with the patient at least 1h / day. This intervention remains not compatible with the investigators care organization because the caregiver can not spend that amount of time with each patient.

Investigators therefore propose to associate CIMT with another top down technique:

visual-spatial cueing (use of panels and/or visual messages to encourage the conscious use of the AA) and investigators want to evaluate the effectiveness of this treatment on learning transfer to ADL.

The objective of our study will be to test the feasibility of setting up such an intervention.

Study Design

Study Type:
Interventional
Actual Enrollment :
8 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Feasibility of Modified Constraint-induced Movement Therapy Combined With Visual-spatial Cueing Strategy in Patients With Acute Stroke
Actual Study Start Date :
Jan 18, 2019
Actual Primary Completion Date :
Feb 12, 2020
Actual Study Completion Date :
Feb 12, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Constraint-induced movement therapy

Patient's unaffected arm is restrained, by a glove including thumb, during activities of daily life (bathing, grooming, dressing and feeding = approx. 4h/day). Visual spatial cueing is displayed in the bedroom and the bathroom.

Other: Constraint-induced movement therapy
Patient's unaffected arm is restrained, by a glove including thumb, during activities of daily life (bathing, grooming, dressing and feeding = approx. 4h/day). Visual spatial cueing is displayed in the bedroom and the bathroom.
Other Names:
  • Visual-spatial cueing : top down
  • No Intervention: Usual care

    Usual care of the neurovascular unit. = No constraint, no cueing, and same physiotherapy intervention as experimental arm.

    Outcome Measures

    Primary Outcome Measures

    1. Number of tasks realized per protocol between the two arms [Day 15]

      Variances to a predetermined checklist

    Secondary Outcome Measures

    1. Arm motor function [Day 0, Day 15 and Month 3]

      Action Research Arm Test

    2. Pain evolution [Day 0, Day 7, Day 15 and Month 3]

      Use of Visual analogue scale to determine the degree of pain on a scale from 0 to 10 (0: meaning no pain, 10 being maximal tolerable pain)

    3. Anxiety and Depression evolution [Day 0, Day 7, Day 15 and Month 3]

      Use of Hospital Anxiety and Depression Scale. This scale has 14 items in total, 7 items for Anxiety and 7 for Depression. Each item is rated from 0 to 3. score of 0 meaning normal, score 3 meaning abnormal.

    4. Situation of patient after neurovascular unit [Month 3]

      Indication of patient 's situation at the end of the study: either Rehabilitation center, Nursing homes, Home or Other

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Hospitalized patient in neurovascular unit for stroke

    • Time since stroke between 2 and 4 days

    • Movement capacity of the upper arm (against gravity) :

    • Ability to extend actively the metacarpophalangeal and interphalangeal joints at least 10°, and the wrist 20°

    • Ability to bend actively the elbow at least 45°

    • Ability to bend and abduct actively the shoulder at least ≥ 45°

    • Age ≥ 18 years old

    • Patient agreement to join the study

    • Patient covered by french social security

    Exclusion Criteria:
    • Excessive spasticity : score > 2 on the modified Ashworth scale

    • Excessive pain in the affected arm : score ≥ 4 on the visual analogue scale

    • Joint limitation on the affected arm

    • Patient under guardianship or curatorship

    • Pregnant or breastfeeding woman

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Service de Neurologie, CHU Nantes Nantes France 44093

    Sponsors and Collaborators

    • Nantes University Hospital

    Investigators

    • Principal Investigator: Ambre Komonski, CHU Nantes

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Nantes University Hospital
    ClinicalTrials.gov Identifier:
    NCT03754166
    Other Study ID Numbers:
    • RC18_0288
    First Posted:
    Nov 27, 2018
    Last Update Posted:
    Dec 16, 2020
    Last Verified:
    Dec 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 16, 2020